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The RNA interference (RNAi) pathway can be exploited 
using short hairpin RNAs (shRNAs) to durably inactivate 
pathogenic genes. Prediction of optimal target sites is 
notoriously inaccurate and current approaches applied 
to HIV-1 show weak correlations with virus inhibition. 
In contrast, using a high-content model for disrupting 
pre-existing intramolecular structure in the HIV-1 RNA, 
as achievable using high-resolution SHAPE (selective 
2′-hydroxyl acylation analyzed by primer extension) 
chemical probing information, we discovered strong 
correlations between inhibition of HIV-1 production in 
a quantitative cell-based assay and very simple thermo-
dynamic features in the target RNA. Strongest inhibition 
occurs at RNA target sites that both have an acces-
sible “seed region” and, unexpectedly, are structurally 
accessible in a newly identified downstream flanking 
sequence. We then used these simple rules to create a 
new set of shRNAs and achieved inhibition of HIV-1 pro-
duction of 90% or greater for up to 82% of designed 
shRNAs. These shRNAs inhibit HIV-1 replication in 
therapy-relevant T cells and show no or low cytotoxicity. 
The remarkable success of this straightforward SHAPE-
based approach emphasizes that RNAi is governed, in 
significant part, by very simple, predictable rules reflect-
ing the underlying RNA structure and illustrates prin-
ciples likely to prove broadly useful in understanding 
transcriptome-scale biological recognition and thera-
peutics involving RNA.
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IntroductIon
Interactions between RNAs and molecular ligands, proteins, and 
other RNAs govern numerous cellular regulatory processes. These 
targeting and binding events are strongly influenced by the struc-
ture of the target RNA.1 One biologically and clinically important 
example of intermolecular interactions between RNAs involves the 
RNA interference (RNAi) pathway.2 The RNAi pathway regulates 
gene expression in organisms from plants to humans3 and immune 
defense via destruction of pathogenic RNAs.4 This pathway can 
be exploited to destroy pathogenic RNAs using synthetic short 
interfering RNA (siRNA) or short hairpin RNA (shRNA) expres-
sion vectors.5 The ~19 nucleotide (nt) guide strands generated 
from cellular transcripts or synthetic RNAs are loaded into the 
RNA-induced silencing complex (RISC). Base complementarity 
between the guide strand and target RNA signals the Argonaute 
protein in RISC to cleave the target RNA. Both siRNA and shRNA 
approaches have been used successfully to inhibit HIV-1 produc-
tion and replication in cell culture.6–8
The pathways for incorporation of siRNAs into RISC and their 
recognition of RNA targets are complex and not all sequences 
can be targeted efficiently. Most randomly selected sequences are 
not efficiently repressed by siRNAs or shRNAs directed against 
them.6,9 Accurate identification of repressible sequences remains 
an unmet challenge that has motivated the development of a 
wide variety of target selection algorithms.9–22 Most algorithms 
were developed for selection of siRNAs and are usually assumed 
to apply to shRNA design, although there is evidence that siRNA 
and shRNA prediction require distinct, but overlapping, rules.23,24 
Degradation of transfected siRNAs in vivo makes them primarily 
suitable for short-term clinical applications, such as the treatment 
of acute infection. In contrast, for stable, long-term suppression 
as likely required for chronic infections, including HIV-1, we 
are especially interested in understanding the rules that govern 
shRNA-directed inhibition.
ter Brake et al.6 reported the ability of 84 shRNA constructs to 
inhibit HIV-1 production in cell culture. This set of inhibitors was 
attractive as a training dataset because it was developed without 
using any si/shRNA selection rules. With a view towards potential 
therapeutic applications, shRNAs were instead chosen based on 
sequence conservation in the HIV-1 RNA. In addition, viral inhi-
bition was assessed at low, generally subsaturating, shRNA trans-
fection levels. As a result, viral inhibition levels achieved by these 
shRNAs spanned a wide range of inhibition levels.
Correlations between virus production inhibition by shRNAs 
in this dataset6 and rankings given by previously described predic-
tion algorithms9,12,14–21 are generally poor. This poor performance 
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includes algorithms both that consider sequence signatures in the 
target RNA sequence and that additionally incorporate thermo-
dynamic metrics to identify favorable interactions between an 
si/shRNA and its target (Table 1).
We therefore sought to explore whether nucleotide-resolu-
tion information about an RNA target structure might make it 
possible to design potent shRNA inhibitors efficiently. We show 
that, if the underlying RNA structure is known with good accu-
racy, very simple thermodynamics-based rules yield excellent 
predictions for highly potent shRNA inhibitors of HIV-1 repli-
cation. Our prediction accuracy exceeds all current approaches 
when applied to the HIV-1 RNA genome, a notable result given 
that the rules developed in this work are much simpler than 
alternative approaches. In broad terms, this work shows how 
profoundly RNA structure influences biological function and 
emphasizes the importance of developing high-content models 




To derive new rules for designing shRNA inhibitors, we focused 
on one of the simplest possible models for the thermodynamics 
of the guide strand-HIV RNA target interaction. In this model 
(Figure 1), the unstructured guide strand binds to a complemen-
tary region of the target RNA to form the guide strand-target 
duplex. We assumed that protein contacts with RISC maintained 
the guide strand in a single-stranded conformation, poised to 
interact with the target RNA. This equilibrium is thus described 
by a free energy change, ΔGduplex, and is calculated using near-
est neighbor-thermodynamic rules.25,26 ΔGduplex depends only on 
the RNA sequence and is independent of RNA structure because 
the unstructured guide strand is assumed to interact with a fully 
unfolded site in the target RNA.
In reality, the target RNA folds back on itself to form base 
paired secondary (and higher order) structures. Thus, a prerequi-
site for effective binding by RISC is that a site in the target RNA be 
unfolded to allow interaction with the guide strand. The strength 
of these pre-existing interactions is termed ΔGtarget (Figure 1). We 
consider a very simple model in which ΔGduplex and ΔGtarget domi-
nate the equilibrium for forming a putative guide strand-target 
RNA interaction. The total free energy change ΔGtotal of the inter-
action reflects a favorable contribution from duplex formation 
and the unfavorable cost of disrupting pre-existing structures in 
the target RNA:
ΔGtotal = ΔGduplex – ΔGtarget (1)
In contrast to ΔGduplex, which is independent of RNA struc-
ture, accurate calculation of the free energy change required to 
unfold the target RNA (∆Gtarget) depends critically on the RNA 
structure model. Conventional thermodynamics-based RNA sec-
ondary structure prediction algorithms typically attain accura-





















Figure 1 the guide strand-target rnA interaction equilibrium. RISC Argonaute protein is represented by an orange oval, although only RNA–RNA 
thermodynamics were considered in this study. RISC, RNA-induced silencing complex.
table 1 correlation between HIV-1 inhibition and si/shrnA target 
prediction algorithms
Algorithm reference |r |
Approaches based primarily on sequence characteristics:
 Amarzguioui 17 0.33
 BIOPREDsi 12 0.30
 Dharmacon 9 0.15
 DSIR 21 0.51
 i-Score 20 0.30
 Katoh 18 0.11
 Takasaki 19 0.05
Approaches that directly incorporate RNA structure metrics:
 RNAxsa 14 0.28
 Sirna 15,16 0.13
Approaches based solely on RNA structure metrics, described in this study:
 No constraints 0.36 (ΔGtarget)
0.38 (ΔGtotal)
 With SHAPE 0.72 (ΔGtarget)
0.61 (ΔGtotal)
Linear correlation coefficient magnitudes |r | for si/shRNA design method scores 
compared to viral inhibition data for the 84-member training dataset used in 
this study.
aSee Methods for additional information.
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RNA length increases.26,27 This level of accuracy provides a helpful 
overall glimpse of an RNA structure but, in the context of HIV-1 
inhibition by shRNAs, is insufficient for consistent prediction of 
optimal guide strand binding sites (Table 1). Secondary struc-
ture predictions can be improved dramatically by incorporating 
additional experimental information. In particular, nucleotide-
 resolution measurements of molecular structure obtained from 
SHAPE (selective 2′-hydroxyl acylation analyzed by primer 
extension) chemical probing experiments28,29 can be incorporated 
as pseudo-free energy corrections into a thermodynamics-based 
RNA folding algorithm.30 The resulting RNA secondary struc-
ture models are generally highly accurate even for RNAs on the 
kilobase scale.27 We therefore used a SHAPE-directed secondary 
structure model of an entire ~9 kb HIV-1 genome31 to calculate 
∆Gtarget.
concentration dependence of shrnA inhibition
Ideally, RNAi-mediated knockdown of a target gene should be 
accomplished using the lowest effective concentration of shRNA, 
for two reasons. First, the RNAi pathway contains a finite comple-
ment of protein mediators, which can become saturated by the 
expression of large amounts of exogenous siRNA. Such saturation 
is thought to be an important cause of off-target effects and of gen-
eral cell toxicity.32,33 Second, artificial production of large amounts 
of guide strand-RISC complexes can increase targeting of subop-
timal sequences and thus obscure important physiological differ-
ences in targetability.
We therefore sought to determine the minimum level of 
transfected shRNA-encoding plasmid that achieved inhibition 
of HIV-1 production in our cell-based assay.6 We titrated plas-
mids expressing five shRNA sequences over the range from 1 to 
125 ng (Figure 2). Individual shRNAs differ significantly in their 
ability to inhibit HIV-1 production and inhibition by a given 
shRNA increased as amount of transfected plasmid increased. 
All five shRNA sequences tested showed significantly stronger 
inhibition at 125 ng transfected plasmid versus 25 ng plasmid. In 
this work, we use 25 ng transfected plasmid because this amount 
showed a high level of knockdown for optimal sequences, was 
subsaturating in our experimental system, and is therefore most 
appropriate for facilitating accurate identification of highly 
potent shRNAs.
Weak target folding energy characterizes  
effectively repressed sequences
Local accessibility has been shown to be an important deter-
minant for efficient si/shRNA-mediated knockdown of a target 
gene14,16,34–37 (see ∆Gtarget, Figure 1). However, it is not obvious 
precisely which portion of the target RNA sequence needs to be 
accessible, or unfolded. An unfolding window is characterized 
by two parameters: its size and position. We calculated the free 
energy change, ΔGtarget, of base pair formation in the SHAPE-
based HIV-1 RNA structure31 as a function of window size and 
position. We then calculated the linear correlation coefficient, 
r, between these ΔGtarget values and the experimental viral pro-
duction inhibition values obtained by ter Brake et al.6 for each of 
the 84 shRNAs in the training set (Figure 3 and Supplementary 
Table S1). The magnitudes of the correlation coefficients quan-
tify the strength of the ΔGtarget metric for predicting inhibition, 

































Figure 2 relative levels of virus production for five shrnAs. shRNA-
encoding plasmids were transfected into 293T cells in amounts ranging 
from 1 to 125 ng per well. Each shRNA is labeled by the first nucleotide 
position of its binding site on the NL4-3 HIV-1 messenger RNA (see 

















































Figure 3 HIV-1 genome locations of the 84 target sequences for the shrnAs in the ter Brake et al. dataset6 used to derive design rules (top) 
and of the 26 sequences, designed by the rules defined in this work (bottom). Numbers indicate the position of the 5′ nucleotide of each shRNA 
target site in the HIV-1 NL4-3 messenger RNA.
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target RNA window that should be unstructured for optimal 
shRNA-mediated inhibition (Figure 4 and Supplementary 
Table S2).
The strongest correlation was obtained for a 13-nt window 
that begins at position 14 of the target RNA (Figure 4a, white box) 
and has an r-value of −0.72 (Figure 5a). The negative correlation 
confirmed that more readily unfolded, or less structured, target 
windows were more readily silenced. The first 5–6 nts of the posi-
tion window overlapped closely with the “seed region”, the guide 
strand sequence that interacts initially with the target RNA before 
complete unfolding of the target to form the ~19-nt long duplex38 
(Figure 1).
Unexpectedly, the 13-nt window also extended seven 
nucleotides beyond the 3′ end of the target RNA binding site 
(Figure 4b, gray box). This indicates that the most effectively 
targeted RNA sequences are characterized by a 13-nt unstruc-
tured window that includes the seed region binding site and a 
previously unrecognized requirement that extends ~7 additional 
nucleotides beyond the region directly bound by the guide 
strand in RISC.
strong total binding energy characterizes effectively 
repressed sequences
The formation of a ~19-nt duplex between guide strand nucle-
otides target is required for proper recognition and subsequent 
cleavage of the target by RISC Argonaute proteins. We estimated 
the strength of this binding as the overall binding free energy 
ΔGtotal of the complete 19-nt interface. We then computed the cor-
relation between ΔGtotal and viral production inhibition for each 
of the shRNAs in the training set. Total binding energy correlated 
strongly with shRNA inhibition (r = 0.61) (Figure 5b).
strong thermodynamic correlations are specific to 
the sHAPe-directed rnA structure model
Strong correlations between HIV-1 inhibition and the ener-
getic cost of disrupting pre-existing structures in the viral RNA 
(ΔGtarget) and for overall strength of guide strand binding (ΔGtotal) 
were obtained when these free energies were calculated using the 
experimentally supported model for an HIV-1 genomic RNA.31 
This model was obtained using authentic genomic RNA gently 
extracted from virions and was used to represent structures at 
any targetable stage in the HIV-1 replication cycle. This SHAPE-
directed model shares only ~45% of base pairs with a model 
obtained using the same nearest-neighbor parameters but without 
experimental data (data not shown).
Using the structure predicted without experimental SHAPE 
constraints, we obtained much weaker correlations between 
viral inhibition and any simple thermodynamic metric for 
guide strand interaction (Supplementary Table S3). The cor-
relations between viral production values for the training set 
 shRNAs and ΔGtarget calculated for the 13-nt window or for 
ΔGtotal, which includes the guide strand-target duplex formation 
interaction, had modest r-values of −0.36 and +0.38, respectively 
(Figure 5c,d). These correlations, although poor, are actually at 
the higher end relative to current si/shRNA prediction algo-
rithms (Table 1), even though these later approaches use more 
complex rules than the very simple thermodynamic approach 






























Figure 4 correlation coefficients (r) between calculated target folding energies, ΔGtarget, and experimental activity values for the 84 shrnAs 
in the training dataset. (a) Linear r-values as a function of target unfolding window size (vertical axis) and position (horizontal axis). Colors denote 
the relative strength of the correlation. A white box highlights the strongest correlation. (b) Optimal accessible target window. Window positions are 
numbered relative to the 5′ end of the guide strand binding site on the target RNA. The window size denotes the length of the window extending 
downstream of the window position value. The accessible target window that yielded the strongest correlation is shown by a gray rectangle.
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These results emphasize that target RNA secondary structure 
plays a profound role in RNAi activity, that current thermody-
namics-only calculations do not recapitulate this contribution, 
and that SHAPE-directed secondary structure prediction provides 
significant additional information.
experimental validation of shrnA design rules
The strong correlations between inhibition of viral production and 
ΔGtarget and ΔGtotal, calculated using the SHAPE-derived secondary 
structure for HIV-1 (Figure 5a,b), suggest two remarkably simple 
rules for shRNA design. First, the target RNA in the newly defined, 
optimal 13-nt window should have minimal pre-existing structure. 
Second, the total binding energy for the guide strand-target RNA 
interaction should be strong. We tested these two rules by design-
ing a new, independent set of shRNA inhibitors and measured their 
ability to inhibit HIV-1 viral production. We calculated ΔGtarget and 
ΔGtotal for all possible 19-nt sequences in the 9,173 nt NL4-3 HIV-1 
genome and initially required ΔGtarget to be greater than or equal to 
0 kcal/mol and ΔGtotal to be less than −25 kcal/mol. Approximately 
500 sequences (~5% of all possible 19-mers) satisfied these two 
rules. Of these, we tested 26 randomly selected sequences (Figure 3, 
bottom; and Supplementary Table S4).
The percentages of shRNAs that achieved a defined level of 
HIV-1 inhibition were calculated for the initial training set and for 
the independently designed test sequences (Figure 6a). Strikingly, 
23 of the 26 shRNAs (88%) selected based on our rules reduced 
HIV-1 production by a factor of two or more. Moreover, this 
simple thermodynamics-based approach was especially successful 
at identifying highly potent inhibitors: 54% (14/26) of the designed 
shRNAs inhibited viral production by 90% or greater (see −25 kcal/
mol data, Figure 6a). Very simple  thermodynamics-based selec-
tion rules thus yielded a dramatic improvement in selection of 
potent shRNAs (compare Figure 6a,b).
The total binding energy plays a major role in governing 
shRNA inhibition. Increasing the stringency of ΔGtotal from −25 to 
−27 and to −29 kcal/mol yields a monotonic increase in predic-
tion success of the most potent shRNA inhibitors in the test set 
(Figure 6a). At the −29 kcal/mol threshold, 82% (9/11) of designed 
shRNAs inhibit viral production by 90% or greater (Figure 6a). In 
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Figure 5 relative viral production versus (a) target folding ener-
gies, ΔGtarget, and (b) total binding energies, ΔGtotal, for the 84 shr-
nAs in the training dataset. The optimal target unfolding window, 
identified in Figure 4, was used for ΔGtarget calculations. The SHAPE-
directed HIV-1 secondary structure model31 was used to calculate 
ΔGtarget. The same correlations for (c) ΔGtarget and (d) ΔGtotal calculated 
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Figure 6 Prediction success rates of designed shrnAs. (a) Inhibition 
of HIV-1 production by shRNAs in the test set. Target sequences were 
chosen to have accessible 13-nucleotide windows (ΔGtarget ≥0 kcal/mol) 
and strong overall binding energy ΔGtotal. Prediction success rates are 
shown for ΔGtotal criteria of −25, −27, and −29 kcal/mol; n, the numbers 
of shRNAs meeting a given threshold. (b) Inhibition of HIV-1 produc-
tion by shRNAs in the 84-member training set. (c) Prediction success 
rates for 16 shRNAs that failed the target accessibility criterion. ΔGtarget <0 
 corresponds to RNA target sites with some pre-existing structure. 
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accessible in the 13-nt optimal window and bind at the ≤ −29 kcal/
mol threshold.
To further evaluate the importance of the target accessibil-
ity rule, we also assayed 16 shRNAs that had total binding ener-
gies < −25 kcal/mol but did not conform to the rules developed 
here because they had nonzero target folding energies in the opti-
mal 13-nt window. Of these sequences, 56% (9/16) reduce HIV-1 
viral production by a factor of two or more but only one of the 
16 shRNAs (6%) resulted in highly potent, greater than 90%, inhi-
bition (Figure 6c). Poor inhibition by these sequences emphasizes 
the importance of an accessible optimal target window for potent 
RNAi-mediated repression.
shrnA repression and toxicity in human t cells
Measuring shRNA-mediated inhibition by the 293T cell transfec-
tion assay used in this study is advantageous because of its quan-
titative accuracy. However, an shRNA-based HIV-1 therapeutic 
will need to be effective in natural host immune cells. We there-
fore used a lentiviral vector to stably transduce a human T cell 
line, SupT1, with single copies of eight selected shRNA expres-
sion constructs identified in our test set. Cells were subsequently 
challenged with low and high doses of HIV-1 and the durability 
of inhibition was monitored (Supplementary Figure S1). In all 
cultures, HIV-1 replication was either completely inhibited or was 
significantly delayed by shRNA expression, whereas HIV-1 repli-
cated efficiently on cells transduced with the empty JS1 vector.
A key concern for therapeutic shRNA use is the potential 
for stimulating unintended off-target and cytotoxic effects. To 
quantify these effects, we transduced SupT1 cells with lentiviral 
constructs expressing this same set of shRNAs and measured the 
impact of lentiviral vector integration and shRNA expression using 
a competitive cell growth assay.39 No negative effect was caused by 
integration of the empty lentiviral vector, as observed previously.39 
Of the shRNA constructs from our test set that were evaluated 
(Supplementary Figure S2), we observed no effects for shRNAs 
1033, 1876, 4308, 4610, and 8302, and only minimal effects on 
SupT1 cell growth for shRNAs 8220 and 8221. Only one shRNA 
(4384) caused a significant reduction in cell growth (of ~4.5%).
In sum, shRNAs identified in the quantitative cell-based assay 
using 293T cells (Figure 6) also inhibit HIV-1 replication when 
stably transduced into T cells (Supplementary Figure S1) and 
generally show no or minimal impairment of cellular replication 
(Supplementary Figure S2).
Partial sHAPe information is sufficient to identify 
potent shrnA inhibitors
The requirement for performing SHAPE to develop a high-
 content secondary structure model is the experimental cost of this 
approach for accurate shRNA design. SHAPE is rapidly becom-
ing easier to perform and, with current mature technologies, it is 
straightforward to obtain structural data for ~500 nts.29 We thus 
evaluated whether obtaining partial SHAPE information might be 
sufficient to identify potent shRNA inhibitors. Prior experience 
emphasizes that there can be very strong “end effects” in RNA 
folding such that incorrect definition of the 5′ and 3′ ends of an 
RNA can cause large refolding at internal sequences. We therefore 
used SHAPE data from two 500-nt regions, each flanked by 1,000 
additional nucleotides of HIV-1 sequence in our folding analysis. 
Two test regions were chosen based on their spanning the larg-
est number of shRNAs in our test set. We folded each of the two 
2,500 nt regions (spanning nts 601–3,100 and 3,201–5,700), using 
SHAPE data for only the central 500 nts (1,601–2,100 and 4,200–
4,700). We then calculated the resulting free energies, ΔGtarget and 
ΔGtotal, for the test shRNAs in these regions. The energy values 
obtained using these partial folds are similar to energies obtained 
when using the complete genome model. In contrast, the struc-
tural models obtained without using SHAPE constraints yield free 
energy values that agree poorly with the SHAPE-directed models 
(Supplementary Table S5). This analysis suggests that shRNA 
design is significantly improved through the inclusion of partial 
SHAPE data for a large RNA.
dIscussIon
Essentially all recognition processes involving RNA are criti-
cally dependent on the underlying base paired secondary (and 
higher-order tertiary) structure. The central role of accessibility 
at single target sites is well established for RNAi-mediated knock-
down.14,16,34–37 Correspondingly, siRNA and shRNA prediction 
methods often incorporate estimates of target site accessibility into 
their algorithms. However, the structure of a long target RNA is 
generally incompletely understood a priori and the resulting cor-
relations between predicted and effective si/shRNAs are often poor 
(Table 1). Given this difficulty, newer algorithms have tended to 
become more complex and to meld thermodynamic calculations 
with sequence signature and heuristic rules. However, these rules, 
applied to shRNA-mediated inhibition of HIV-1 production, do 
not consistently identify potent inhibitors.
In this work, we find that an extremely simple approach, 
involving the calculation of two straightforward thermodynamic 
terms, significantly outperforms existing approaches when applied 
to inhibition of HIV-1 (Table 1). Our model considered only two 
simple RNA–RNA interactions central to the RISC ribonucleo-
protein machinery (Figure 1). Strong inhibition correlated with 
weak free energies of target folding (r = −0.72) within an optimal 
13-nt window (Figure 4b, gray bar) and with strong total bind-
ing energy (r = 0.61). These correlations were much weaker when 
SHAPE data was not used to direct calculation of the target HIV-1 
RNA secondary structure model (Figure 5 and Table 1), high-
lighting the requirement for an accurate target RNA structure in 
selection of shRNAs.
The correlation coefficient for our total binding energy met-
ric is moderately weaker than that for the target folding energy 
metric (|r| = 0.61 versus 0.72, respectively). However, requiring 
stronger ΔGtotal improves the prediction success rate for sequences 
containing an optimal, fully accessible target window. In addi-
tion, sequences with strong ΔGtotal but less accessible optimal tar-
get windows were rarely potently repressed (Figure 6c). Thus, a 
completely accessible optimal window appears critical for efficient 
repression and, once this condition is met, strong total binding 
energy improves prediction accuracies.
The correlations are consistent with models of target RNA 
association with the guide strand that involve an initial interac-
tion with the seed region, followed by propagation to form a 
duplex containing all guide strand nucleotides (Figure 1).38,40,41 
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Our data also identify a previously unrecognized feature in 
which the optimal accessible target window extends seven nucle-
otides downstream of the seed region binding site (Figure 4). 
The required lack of secondary structure in this region of the 
target RNA may reflect unexplored interactions involving pro-
tein components of RISC.
Many RNAi design criteria are based on specific sequence 
signatures found more frequently in effectively repressed shRNA 
targets. Some of these signatures are consistent with the results of 
the present study. In particular, the observed preference for (more 
weakly pairing) A/U nucleotides at the 3′ end of the target bind-
ing interface,9,42,43 sometimes termed the asymmetry rule, likely 
corresponds to a qualitative sequence signature for an accessible 
seed region, which we quantify as ΔGtarget. Our work emphasizes 
that strong correlations can be obtained using structure-based 
thermodynamic metrics without considering sequence character-
istics, and likely reflects a more direct physical basis for observed 
sequence effects.
In designing shRNAs to test our two structure-based design 
principles, we ignored other design criteria. Consequently, 
many of our successful test shRNAs violate sequence-based 
si/shRNA design principles identified in previous studies. These 
include having an A/U at position 10 of the guide strand to 
facilitate cleavage at this site44 and avoidance of consecutive 
runs of identical nucleotides. Nevertheless, our tested shRNAs 
achieved highly potent HIV-1 inhibition (Figure 6a), suggest-
ing that these sequence-based design rules have limited appli-
cability in this system.
There were two distinctive features of this study that may 
explain differences, and the relative success of our simple approach, 
as compared to prior work.
First, several prediction algorithms have emphasized the role of 
pre-existing target RNA structure in reducing RNAi efficiency14–16,22 
and have obtained good siRNA predictions in the systems studied. 
However, we find that these measures of target accessibility do not 
correlate with shRNA-mediated knockdown for the training data-
set used in our study (Table 1). The importance of structural acces-
sibility and for an accurate model of secondary structure in the 
target RNA may vary with the targeted system and it appears to be 
especially critical in the context of shRNA-mediated inhibition of 
the highly structured31 HIV-1 RNA genome.
Second, RNAi-mediated knockdown is highly sensitive to the 
effective concentration of the si/shRNA. Higher concentrations 
of shRNA yield increased inhibition (Figure 2 and ref. 8) but 
also potentially contribute to saturation of the RNAi machinery, 
yield off-target effects, and stimulate cytotoxic innate immune 
responses.32,33 We therefore focused on shRNA-mediated inhibi-
tion at subsaturating amounts of transfected shRNA constructs. 
Importantly, when we probed cytotoxic effects induced by shRNA 
transduction of SupT1 T cells using a sensitive competitive cell 
growth assay,39 we found that all but one designed shRNA showed 
no or minimal reduction in cell growth.
The use of subsaturating shRNA amounts may also permit the 
simultaneous expression of several different shRNAs and thereby 
reduce the chance of developing escape mutants. This is an espe-
cially important consideration for clinical applications when tar-
geting rapidly mutating viruses such as HIV-1 with RNAi-based 
gene therapies.45,46 Potential shRNA-based therapeutics will have 
to function in human T cells, the natural HIV-1 host. While we 
used human 293T cells in our quantitative virus production inhi-
bition studies, the potent shRNA inhibitors that we identified 
in 293T cells were generally able to inhibit HIV-1 replication in 
human SupT1 T cells, consistent with the observation that deter-
minants of shRNA repression appear to be conserved between 
evolutionarily disparate cell types.42
In sum, an extremely simple model is sufficient to identify 
potent shRNAs that strongly inhibit HIV-1 production in cell cul-
ture, even when the shRNAs are used at subsaturating concen-
trations. These sequences are strong candidate targets for further 
evaluation in preclinical anti-HIV assays. Critically, our approach 
emphasizes the profound role of RNA structure in tuning RNAi 
function and absolutely requires an accurate secondary structure 
model of the RNA target, as obtainable from SHAPE chemical 
probing information. The inclusion of partial SHAPE data, cor-
responding to that obtainable in a single experiment covering 
~500 nts, also yields significant improvements in identification of 
potent shRNA inhibitors. In the broadest terms, this work shows 
how profoundly RNA structure influences biological function 
and emphasizes that, if a high- content model for an RNA fold 
is obtained experimentally, deep insight into underlying mecha-
nisms can be obtained.
MAterIAls And MetHods
Plasmid constructs. The shRNA expression plasmids pSuper-shRNA 
were constructed as described,47 were verified by sequencing, and were 
expected to yield 19-nt guide strands upon processing by the cellular 
miRNA biogenesis pathway. The pLAI plasmid was used to express the 
HIV-1 isolate LAI (GenBank accession K02013). The pRL-CMV plasmid 
(Promega, Madison, WI) expressing Renilla luciferase was cotransfected 
to control for transfection efficacy. For shRNA titration experiments, the 
pBluescript plasmid (Stratagene, La Jolla, CA) was used to normalize plas-
mid amounts.6 To generate lentiviral vectors expressing the  shRNAs, the 
H1-shRNA cassettes were cloned into the lentiviral vector JS1 (pRRLcppt-
pgkgfppreSsin),48 as described previously.6 JS1 harbors a GFP cassette for 
easy identification of transduced cells. For lentivirus production, the JS1 
variants were cotransfected with the packaging plasmids pSYNGP, pVSVg, 
and 250 ng pRSV-rev.
Cell culture. Human embryonic kidney 293T adherent cells were grown 
in Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal calf 
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin in a humidified 
chamber at 37 °C and 5% CO2. The SupT1 T cell line was maintained in 
Advanced RPMI (Gibco, Carlsbad, CA) supplemented with l-glutamine, 
1% fetal calf serum, 30 U/ml penicillin and 30 µg/ml streptomycin; cells 
were maintained at 37 °C and 5% CO2.
Transfections and HIV-1 production experiments. For the HIV-1 pro-
duction assay, cotransfections of pLAI and the shRNA vector were per-
formed in a 24-well format. On the first day, 1.5 × 105 293T cells were 
seeded per well in Dulbecco’s modified Eagle’s medium without antibiot-
ics. The next day, 250 ng pLAI, 25 ng of shRNA vector, and 1 ng pRL-CMV 
in Lipofectamine 2000 (Invitrogen, Carlsbad, CA; following the manufac-
turer’s protocol) were added. After 48 hours, samples of cell supernatant 
were taken for CA-p24 ELISA quantification and cells were lysed for mea-
surement of Renilla luciferase activity (Renilla Luciferase Assay System; 
Promega). All transfections were carried out in duplicate and repeated 
twice. Negative controls were performed using an empty pSuper vector 
and with an shRNA directed against the firefly luciferase gene. Positive 
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inhibition controls were performed using shRNAs directed against known 
efficiently repressed HIV-1 targets (LDR9, GagC, Pol1, and Nef19).6 For 
shRNA titrations, 250 ng pLAI was cotransfected with 1–125 ng pSuper 
shRNA variants and 1 ng pRL-CMV. Variable amounts of pBluescript were 
added to yield equivalent DNA concentrations per transfection. All data 
from transfection experiments were corrected with factor correction to 
compensate for interexperimental differences.49
For lentivirus production, 293T cells were seeded in a 6-well plate 
format 1 day before transfection to reach 70% confluency and subsequently 
transfected with 950 ng lentiviral plasmid JS1-shRNA or empty JS1, 600 ng 
pSYNGP, 330 ng pVSVg, and 250 ng pRSV-rev with Lipofectamine 2000, 
as described.6
The HIV-1 virus stock was produced in 293T cells, which were seeded 
in a T75 flask to yield 70% confluency 1 day before transfection; 40 µg 
HIV-1 pLAI was transfected following the Lipofectamine 2000 protocol 
and supernatant was harvested at 48 hours post-transfection. Cells were 
removed by centrifugation (4,000g) and the supernatant was aliquoted 
and stored at −80 °C. The HIV-1 LAI virus stock was quantified for CA-
p24 by ELISA measurement.
Lentiviral transduction, HIV-challenge experiments, and competitive 
cell growth assay. First, lentiviral titers were determined via titration on 
SupT1 cells, scoring the percentage of green fluorescent protein (GFP)-
positive cells by fluorescence-activated cell sorting.6 Then, a multiplicity 
of infection of 0.15 was used for transduction of SupT1 T cells.6 Four days 
later, cells were sorted for GFP-expression by fluorescence-activated cell 
sorting. 2 × 105 transduced SupT1 cells were challenged with HIV-1 (0.01 
or 0.05 ng CA-p24, corresponding to low and high titers, respectively) and 
monitored daily for up to 90 days by eye and light microscopy to score for 
cytopathic effects. Supernatants were collected in parallel three times per 
week to determine CA-p24 levels. Transduced SupT1 cells were screened 
for a negative impact on the cell growth as induced by lentiviral integra-
tion (JS1 control cells) and shRNA expression using the competitive cell 
growth assay.39 In brief, SupT1 cells were transduced to obtain around 
30% GFP+ cells. The GFP+/GFP− ratio was analyzed over a 30-day period 
by fluorescence-activated cell sorting measurement, and the ratio at day 
3 was normalized to one. Impact on cell growth can be converted as per-
centage reduction in cell growth.39
Free energy calculations. Free energies were calculated using the 
OligoWalk algorithm in the RNAstructure package.50 OligoWalk takes 
an RNA secondary structure model as input and considers a bimolecular 
equilibrium between this folded RNA and every possible complemen-
tary RNA oligonucleotide of a user-defined length. The duplex anneal-
ing energy ΔGduplex and target unfolding energy ΔGtarget are calculated. We 
assumed that shRNAs were cleaved into 19-nt guide strands. The target 
unfolding energy ΔGtarget was calculated as the energy required to break 
base pairs in the input secondary structure model (break local structure 
option in OligoWalk). The structural model was inputted in connect file 
(.ct) format. Our SHAPE-based secondary structure model differs from 
the published model31 in two regions: the transfer RNA primer and a 
heuristically predicted pseudoknot are absent in our input file because 
OligoWalk only permits single molecule inputs and does not allow 
pseudoknots. We excluded shRNA target sequences in these two regions 
because removal of their binding partners resulted in falsely weak target 
folding energies and falsely strong total binding energies; these regions 
are very inaccessible and thus poor candidates for RNAi targets.31 We also 
created a secondary structure model of the NL4-3 HIV-1 RNA using only 
thermodynamic parameters by folding the RNA in RNAstructure without 
any experimental constraints. Perl scripts were created to vary the length 
and position parameters by changing the input oligomer length and by 
shifting the target energy window relative to the guide strand binding site, 
respectively.
Correlation calculations for other algorithms. We calculated correlation 
coefficients between our 84 member-training dataset and siRNA design 
algorithm scores using the i-Score Designer tool (http://www.med.
nagoya-u.ac.jp/neurogenetics/i_Score/i_score.html) for all methods except 
for RNAxs and Sirna. Sirna scores were calculated using the online Sfold 
package (http://sfold.wadsworth.org). We applied the RNAxs algorithm 
using Perl scripts generously provided by the Hofacker lab. The RNAxs 
algorithm evaluates siRNA sequences by filters which include accessibil-
ity criteria. Twenty-one of our 84 training set sequences were predicted to 
be good inhibitors by RNAxs. Of these 21 sequences, 10 (48%) inhibited 
HIV-1 production by more than 50% and 4 (19%) showed greater than 
90% inhibition. To compute the linear correlation coefficient between 
RNAxs ranks for all 84 training sequences and the experimental inhibi-
tion data (Table 1), RNAxs filters were set to zero.
Viral production datasets. We used fully independent datasets to train 
and test our rules (Figure 3). Our training dataset was comprised of the 
shRNA sequences previously published by ter Brake et al.6 Viral pro-
duction values were obtained using relatively low plasmid transfection 
amounts (20 ng) and sequences were chosen without using si/shRNA 
selection rules; instead, sequences were selected based on sequence con-
servation among HIV-1 isolates. A total of 86 HIV-1 sequences were 
targeted by the shRNAs in this dataset. However, two sequences were, 
by coincidence, identical (Supplementary Table S1, asterisks). In the 
current study, we averaged the viral production values for the identical 
sequences and used the resulting 84 sequences in our correlation calcula-
tions. The 26-member test dataset was created as described in the text by 
applying the two thermodynamic rules derived from the training dataset. 
As with the training dataset, no additional si/shRNA design rules were 
invoked.
suPPleMentArY MAterIAl
Figure S1. Inhibition of HIV-1 replication in transduced SupT1 T cells. 
Cells were transduced with the empty JS1 lentivirus (negative control), 
JS1-shPol1 (a known effective inhibitor),6 or lentiviral variants express-
ing eight shRNAs randomly selected from among the most potent test 
set shRNAs. Cultures with CA-p24 amounts above a 1 ng/ml threshold 
were scored as positive for viral replication. The color code indicates 
when virus replication was apparent: within 1 week (white), 2 weeks 
(light gray), 3 weeks (dark gray), or no observable replication for up to 
2 months (black).
Figure S2. Competitive cell growth curves of representative potent 
shRNAs from the test set. SupT1 T cells were transduced with lentiviral 
vectors expressing both shRNA and GFP and cultured together with 
nontransduced SupT1 T cells. To score effects induced by the lentiviral 
integration, cells were transduced with the empty JS1 vector express-
ing GFP but no shRNA. FACS measurements were used to quantify 
GFP+ and GFP− cell populations, corresponding to transduced and 
nontransduced cells, respectively. The GFP+/GFP− ratio (y-axis), quan-
tifies cell growth defects.39 
Table S1. shRNA training dataset sequences and their relative viral 
production values.6
Table S2. Linear correlation coefficients (r) between duplex anneal-
ing energies ΔGduplex, target folding energies ΔGtarget, and total binding 
energies ΔGtotal and HIV-1 inhibition activity values for the 84 shRNAs 
in the training dataset6 calculated using a SHAPE-directed secondary 
structure model.31
Table S3. Linear correlation coefficients (r) between calculated du-
plex annealing energies ΔGduplex, target folding energies ΔGtarget, and 
total binding energies ΔGtotal and experimental activity values for the 
84 shRNAs in the training dataset6 but calculated without using experi-
mental information to derive the secondary structure model.
Table S4. shRNA test dataset core sequences designed using the two 
thermodynamic rules identified in this study and their relative viral pro-
duction values.
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Table S5. Free energy values for test shRNA sequences calculated 
 using two 2,500 nt folds of HIV-1 genome segments.
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